drugset / Trial / NCT00196989
Study In People With Type 2 Diabetes
RandomizedParallel-groupDouble-blindTreatment
Summary
This Phase 2 dose-ranging study will evaluate the efficacy, safety and tolerability of a range of doses of GW677954 compared with placebo over sixteen weeks of treatment in subjects with T2DM (Type 2 Diabetes Mellitus).
Timeline
- Start
- 2005-09
- Primary completion
- 2007-04
- Completion
- 2007-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SODELGLITAZAR | Small molecule | 2.5 mg | Oral |
| Subject | SODELGLITAZAR | Small molecule | 5 mg | Oral |
| Subject | SODELGLITAZAR | Small molecule | 10 mg | Oral |
| Subject | SODELGLITAZAR | Small molecule | 15 mg | Oral |
| Subject | SODELGLITAZAR | Small molecule | 20 mg | Oral |